Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Kathryn A. Bylow MD

Kathryn A. Bylow MD profile photo picture

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Member of the Cancer Center

Publications (25)

  • Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors. (Awoyinka I, Sheean P, Papanek P, Flynn KE, Bylow K, Kilari D, Gann P, Banerjee A, Stolley M) Contemp Clin Trials 2026 Feb;161:108205 PMID: 41453520 PMCID: PMC12987546 SCOPUS ID: 2-s2.0-105027232337 12/27/2025    
  • Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. (Graff JN, Burotto M, Fong PC, Pook DW, Zurawski B, Manneh Kopp R, Salinas J, Bylow KA, Kramer G, Ratta R, Kwiatkowski M, Retz M, Kwak C, Arranz Arija JA, Gurney H, Matsubara N, Villanueva L, Todenhöfer T, Liang LW, Todoric J, Imai K, Stenzl A, KEYNOTE-641 Investigators) Ann Oncol 2025 Aug;36(8):976-987 PMID: 40383193 SCOPUS ID: 2-s2.0-105008902157 05/19/2025       15 Citations
  • Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases. (Thapa B, Shreenivas A, Bylow K, Chen HZ, George B, Kurzrock R) J Immunother Precis Oncol 2024 Nov;7(4):308-313 PMID: 39524464 PMCID: PMC11541926 SCOPUS ID: 2-s2.0-85208714820 11/14/2024       2 Citations
  • An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer. (Kamaraju S, McKoy J, Williams GR, Gilmore N, Minami C, Bylow K, Rajalingam H, Cortina CS, Beckert A, Stolley M, Bullock D, Kurzrock R, Jatoi A) Curr Oncol Rep 2024 Aug;26(8):855-864 PMID: 38801612 PMCID: PMC11300154 SCOPUS ID: 2-s2.0-85194589535 05/27/2024       1 Citation
  • A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC). (Kilari D, Kadambi SG, Baran AM, Zittel J, Burfeind JD, Messing EM, Van Veldhuizen PJ, Bylow KA, Sahasrabudhe DM, Mohile SG, Fung C) Journal of Clinical Oncology 2024;42(16_suppl):5089-5089 SCOPUS ID: 2-s2.0-105024233170 01/01/2024    
  • Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. (Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF) Pract Radiat Oncol 2021;11(6):527-533 PMID: 33848618 PMCID: PMC8638529 SCOPUS ID: 2-s2.0-85107984420 04/14/2021       5 Citations
  • Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. (Pierro M, Raychaudhuri R, Lea WB, Rilling W, Davis N, Bylow K, Kilari D) Clin Genitourin Cancer 2021 Feb;19(1):87-91 PMID: 32778506 SCOPUS ID: 2-s2.0-85089247313 08/12/2020       1 Citation
  • The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? (Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D) Clin Genitourin Cancer 2020 Aug;18(4):e478-e483 PMID: 32085986 SCOPUS ID: 2-s2.0-85079745146 02/23/2020       5 Citations
  • The relationship between anxiety about prostate cancer among patients with biochemical cancer recurrence and the use of complementary and alternative medicines, diet, and exercise (Lee RT, Hemmerich JA, Kwon N, Bylow K, Stadler WM, Mohile SG, Dale W) Family Medicine and Community Health 1 July 2017;5(2):139-148 SCOPUS ID: 2-s2.0-85029633078 07/01/2017       2 Citations
  • Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. (Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D) Clin Genitourin Cancer 2017 Oct;15(5):e897-e901 PMID: 28645484 SCOPUS ID: 2-s2.0-85020921698 06/25/2017       15 Citations
  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643 SCOPUS ID: 2-s2.0-84896710555 01/09/2014       15 Citations
  • Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 01;120(5):692-701 PMID: 24249435 SCOPUS ID: 2-s2.0-84896703767 11/20/2013       96 Citations
  • The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. (Ramsdale E, Polite B, Hemmerich J, Bylow K, Kindler HL, Mohile S, Dale W) J Am Geriatr Soc 2013 Nov;61(11):2043-4 PMID: 24219208 SCOPUS ID: 2-s2.0-84887505934 11/14/2013       14 Citations
  • Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. (Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W) Urology 2011 Apr;77(4):934-40 PMID: 21269665 PMCID: PMC3074039 SCOPUS ID: 2-s2.0-79953849203 01/29/2011       60 Citations
  • Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer (Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stadler WM) Journal of Geriatric Oncology June 2010;1(1):13-19 SCOPUS ID: 2-s2.0-77953783824 06/01/2010       3 Citations
  • WITHDRAWN: Cognitive effects of androgen deprivation therapy in an older cohort of men with prostrate cancer. (Mohile SG et al.) Crit Rev Oncol Hematol 2009 May 14: PMID: 19446466 05/19/2009    
  • Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. (Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM) J Clin Oncol 2009 Apr 01;27(10):1557-63 PMID: 19255325 PMCID: PMC2738613 SCOPUS ID: 2-s2.0-63749112245 03/04/2009       51 Citations
  • Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. (Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF) Clin Genitourin Cancer 2009 Jan;7(1):39-42 PMID: 19213667 SCOPUS ID: 2-s2.0-65249089759 02/14/2009       18 Citations
  • Management of complications of androgen deprivation therapy in the older man. (Mohile SG, Mustian K, Bylow K, Hall W, Dale W) Crit Rev Oncol Hematol 2009 Jun;70(3):235-55 PMID: 18952456 PMCID: PMC3074615 SCOPUS ID: 2-s2.0-67349141307 10/28/2008       71 Citations
  • Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. (Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG) Urology 2008 Aug;72(2):422-7 PMID: 18561991 PMCID: PMC3032402 SCOPUS ID: 2-s2.0-48349102661 06/20/2008       140 Citations
  • Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. (Bylow K, Mohile SG, Stadler WM, Dale W) Cancer 2007 Dec 15;110(12):2604-13 PMID: 17960609 SCOPUS ID: 2-s2.0-37049038470 10/26/2007       113 Citations
  • Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. (Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ) BJU Int 2007 Jul;100(1):70-5 PMID: 17552955 SCOPUS ID: 2-s2.0-34249950226 06/08/2007       52 Citations
  • Pancreatic cancer: an update. (Kindler HL) Curr Oncol Rep 2007 May;9(3):170-6 PMID: 17430687 SCOPUS ID: 2-s2.0-34248401996 04/14/2007       31 Citations
  • A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. (Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M) Cancer 2007 Feb 15;109(4):802-10 PMID: 17219443 SCOPUS ID: 2-s2.0-33846905273 01/16/2007       232 Citations
  • Temporal arteritis: The importance of recognizing senescent changes versus quiescent disease in a temporal artery biopsy. (Bylow KA, Brauner DJ) J Am Geriatr Soc 2006 Dec;54(12):1959-60 PMID: 17198518 SCOPUS ID: 2-s2.0-33845490688 01/03/2007       1 Citation
    • Last update: 03/20/2026